In vivo characterization of a dual adenosine A2A/A1 receptor antagonist in animal models of Parkinson's disease

Journal of Medicinal Chemistry

Volumn 53, Issue 22, 2010, Pages 8104-8115

  Shook, Brian C ^a   Rassnick, Stefanie ^a   Osborne, Melville C ^a   Davis, Scott ^a   Westover, Lori ^a   Boulet, Jamie ^a   Hall, Daniel ^a   Rupert, Kenneth C ^a   Heintzelman, Geoffrey R ^a   Hansen, Kristin ^a   Chakravarty, Devraj ^a   Bullington, James L ^a   Russell, Ronald ^a   Branum, Shawn ^a   Wells, Kenneth M ^a   Damon, Sandra ^a   Youells, Scott ^a   Li, Xun ^a   Beauchamp, Derek A ^a   Palmer, David ^a   Reyes, Mayra ^a   Demarest, Keith ^a   Tang, Yuting ^a   Rhodes, Kenneth ^a   Jackson, Paul F ^a   more..

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 4 PHENYL 8 (PYRROLIDIN 1 YLMETHYL) 5H INDENO[1,2 D]PYRIMIDIN 5 ONE; ADENOSINE A1 RECEPTOR ANTAGONIST; ADENOSINE A2A RECEPTOR ANTAGONIST; ANTIPARKINSON AGENT; BENSERAZIDE; CARBIDOPA; ISTRADEFYLLINE; LEVODOPA; UNCLASSIFIED DRUG;

AKINESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATALEPSY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG POTENCY; DRUG SYNTHESIS; EXPERIMENTAL MONKEY; FEMALE; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PARKINSON DISEASE; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADENOSINE A1 RECEPTOR ANTAGONISTS; ADENOSINE A2 RECEPTOR ANTAGONISTS; ADMINISTRATION, ORAL; ANIMALS; ANTIPARKINSON AGENTS; CALLITHRIX; DISEASE MODELS, ANIMAL; FEMALE; INDENES; MACACA FASCICULARIS; MALE; MICE; MICE, INBRED BALB C; PARKINSON DISEASE; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ADENOSINE A2A;

EID: 78649499608     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm100971t     Document Type: Article

References (60)

1. Lozano, A. M.; Lang, A. E.; Hutchison, W. D.; Dostrovsky, J. O. New developments in understanding the etiology of Parkinson's disease and in its treatment Curr. Opin. Neurobiol. 1998, 8, 783-790
2. 2 dopamine receptors in rat striatum Mol. Brain Res. 1992, 14, 186-195
3. 2receptor mRNA in the human brain Neurosci. Lett. 1991, 130, 177-181
4. Olanow, C. W. MAO-B inhibitors in Parkinson's disease Adv. Neurol. 1993, 60, 666-671
5. Gordin, A.; Brooks, D. J. Clinical pharmacology and therapeutic use of COMT inhibition in Parkinson's disease J. Neurol. 2007, 254, IV/37-IV/48
6. Olanow, C. W.; Stocchi, F. COMT inhibitors in Parkinson's disease. Can they prevent and/or reverse levodopa-induced motor complications? Neurology 2004, 62, S72-S81
7. Antonini, A.; Clilia, R. Behavioural adverse effects of dopaminergic treatments in Parkinson's disease: incidence, neurobiological basis, management and prevention Drug Safety 2009, 32, 475-488
8. Hansard, M. J.; Smith, L. A.; Jackson, M. J.; Cheetham, S. C.; Jenner, P. Dopamine, but not norepinephrine or serotonin, reuptake inhibition reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates J. Pharmacol. Exp. Ther. 2002, 303, 952-958
9. Antonini, A.; Tolosa, E.; Mizuno, Y.; Yamamoto, M.; Poewe, W. H. A reassessment of risks and benefits of dopamine agonists in Parkinson's disease Lancet Neurol. 2009, 8, 929-937
10. Yamamoto, M.; Schapira, A. H. V. Dopamine agonists in Parkinson's disease Expert Rev. Neurother. 2008, 8, 671-677
11. 2A antagonists 1,2,4-triazolo[1,5- c ]pyrimidines Bioorg. Med. Chem. Lett. 2009, 19, 967-971
12. 2A receptor antagonists with in vivo activity J. Med. Chem. 2008, 51, 400-406
13. 2A receptor antagonists Bioorg. Med. Chem. Lett. 2009, 19, 1399-1402
14. 2A receptor antagonists J. Med. Chem. 2004, 47, 4291-4299 (Pubitemid 39045435)
15. Latini, S.; Pedata, F. Adenosine in the central nervous system: release mechanisms and extracellular concentrations J. Neurochem. 2001, 79, 463-484
16. Dunwiddie, T. V.; Masino, S. A. The role and regulation of adenosine in the central nervous system Annu. Rev. Neurosci. 2001, 24, 31-55
17. Stiles, G. L. Adenosine receptors J. Biol. Chem. 1992, 267, 6451-6454
18. 2A receptors in rat central nervous system J. Comp. Neurol. 1998, 401, 163-186
19. 2A receptors-where are they? What do they do? Comments Trends Pharmacol. Sci. 1998, 19, 46-47
20. 11C]TMSX Synapse 2005, 55, 133-136
21. Svenningsson, P.; Hall, H.; Sedvall, G.; Fredholm, B. B. Distribution of adenosine receptors in the postmortem human brain: an extended autoradiographic study Synapse 1997, 27, 322-335
22. Pollack, A. E.; Fink, J. S. Adenosine antagonists potentiate D2 dopamine dependent activation of Fos in the striatopallidal pathway Neuroscience 1995, 68, 721-728
23. 2A adenosine receptor inactivation in a model of Parkinson's disease J. Neurosci. 2001, 21, RC143/1-RC143/6
24. 2A receptor antagonist in MPTP-treated monkeys Neurology 1999, 52, 1673-1677
25. 2A adenosine receptor antagonists on motor dysfunction and neurodegenerative processes Drug Dev. Res. 2001, 52, 379-386
26. 2A receptor blockade in experimental models of Parkinson's disease J. Neurochem. 2002, 80, 262-270
27. 2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys Ann. Neurol. 1998, 43, 507-513
28. 2A receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats Eur. J. Pharmacol. 2000, 408, 249-255
29. 2A antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys Exp. Neurol. 2000, 162, 321-327
30. 2A receptor antagonist istradefylline in advanced PD Neurology 2003, 61, 297-303
31. 2A receptor antagonist treatment of Parkinson's disease Neurology 2003, 61, 293-296
32. 1 receptor agonist, on spontaneous and evoked dopamine release in rat neostriatum Neurosci. Lett. 1995, 185, 29-32
33. Moore, K. A.; Nicoll, R. A.; Schmitz, D. Adenosine gates synaptic plasticity at hippocampal mossy fiber synapses Proc. Nat. Acad. Sci. U.S.A. 2003, 100, 14397-14402
34. 1 receptors in nerve terminal and synapses of the rat hippocampus Brain Res. 2003, 987, 49-58
35. 1 receptors J. Pharmacol. Sci. 2004, 96, 42-52
36. 1 antagonists Bioorg. Med. Chem. Lett. 2010, 20, 2864-2867
37. 1 antagonists Bioorg. Med. Chem. Lett. 2010, 20, 2868-2871
38. Zarrindast, M. R.; Modabber, M.; Sabetkasai, M. Influence on different adenosine receptor subtypes on catalepsy in mice Psychopharmacology 1993, 113, 257-261
39. 2 receptors modulate haloperidol-induced catalepsy in rats Eur. J. Pharmacol. 1997, 328 (2/3) 135-141
40. Cooper, D. R.; Marrel, C.; van de Waterbeemd, H.; Testa, B.; Jenner, P.; Marsden, C. D. L-Dopa esters as potential prodrugs: behavioral activity in experimental models of Parkinson's disease J. Pharm. Pharmacol. 1987, 39, 627-635
41. Ungerstedt, U. 6-Hydroxydopamine-induced generation of central monoamine neurons Eur. J. Pharmacol. 1968, 5, 107-110
42. Ungerstedt, U.; Arbuthnott, G. W. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system Brain Res. 1970, 24, 485-493
43. Luthman, J.; Fredriksson, A.; Sundstroem, E.; Jonsson, G.; Archer, T. Selective lesion of central dopamine or moradenaline neuron systems in the neonatal rat: motor behavior and monoamine alteration at adult stage Behav. Brain Res. 1989, 33, 267-277
44. Bankiewicz, K. S. MPTP-induced parkinsonism in nonhuman primates Methods Neurosci. 1991, 7, 168-182
45. Jakowec, M. W.; Petzinger, G. M. 1-Methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced lesion model of Parkinson's disease, with emphasis on mice and nonhuman primates Comp. Med. 2004, 54, 497-513
46. Campos-Romo, A.; Ojeda-Flores, R.; Moreno-Briseno, P.; Fernandez-Ruiz, J. Quantitative evaluation of MPTP-treated nonhuman parkinsonian primates in the hallway task J. Neurosci. Methods 2009, 177, 361-368
47. Kraus, G. A.; Sy, J. O. A synthetic approach to rocaglamide via reductive cyclization of δ-keto nitriles J. Org. Chem. 1989, 54, 77-83
48. 2a Receptor Antagonists. PCT Int. Appl. WO 2005042500, 2005.
49. Yu, Y.; Liebeskind, L. S. Copper-mediated, palladium-catalyzed coupling of thiol ester with aliphatic organoboron reagents J. Org. Chem. 2004, 69, 3554-3557
50. Kusturin, C.; Liebeskind, L. S.; Rahman, H.; Sample, K.; Schweitzer, B.; Srogl, J.; Neumann, W. L. Switchable catalysis: modular synthesis of functionalized pyrimidones via selective sulfide and halide cross-coupling chemistry Org. Lett. 2003, 5, 4349-4352
51. Liebeskind, L. S.; Srogl, J. Heteroaromatic thioether-boronic acid cross-coupling under neutral reaction conditions Org. Lett. 2002, 4, 979-981
52. Hyttel, J.; Larsen, J. J.; Christensen, A. V.; Arnt, J. Recptor-binding profiles of neuroleptics Psychopharmacol. Suppl. 1985, 2, 9-18
53. 2A receptors modify motor function in MPTP-treated common marmosets NeuroReport 1998, 9, 2857-2860
54. 2A receptor antagonist in MPTP-treated monkeys Neurology 1999, 52, 1673-1677
55. 2A receptor antagonist treatment of Parkinson's disease Neurology 2003, 61, 293-296
56. 2A receptor antagonist istradefylline in advanced PD Neurology 2003, 61, 297-303
57. Marsden, C. D.; Dolphin, A.; Duvoisin, R. C.; Jenner, P.; Tarsy, D. Role of noradrenaline in levodopa reversal of reserpine akinesia Brain Res. 1974, 17, 521-525
58. Starr, M. S.; Starr, B. S. Comparison of the effects NMDA and AMPA antagonist on the locomotor activity induced by selective D1 and D2 dopamine agonists in reserpine-treated mice Psychopharmacology 1994, 114, 495-504
59. Robinson, T. E.; Becker, J. B. The rotational behavior model: asymmetry in the effects of unilateral 6-OHDA lesions of the substantia nigra in rats Brain Res. 1983, 264, 127-131
60. Damier, P.; Hirsch, E. C.; Agid, Y.; Graybiel, A. M. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease Brain 1999, 122, 1437-1448